Piper Sandler Maintains Overweight on Taysha Gene Therapies, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) but lowers the price target from $9 to $7.
July 01, 2024 | 10:51 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Taysha Gene Therapies but has lowered the price target from $9 to $7.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100